Hydrolysis of capecitabine to 5′-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide

Sara Quinney, S. P. Sanghani, W. I. Davis, Thomas Hurley, Z. Sun, D. J. Murry, William F. Bosron

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Capecitabine is an oral prodrug of 5-fluorouracil that is indicated for the treatment of breast and colorectal cancers. A three-step in vivo-targeted activation process requiring carboxylesterases, cytidine deaminase, and thymidine phosphorylase converts capecitabine to 5-fluorouracil. Carboxylesterases hydrolyze capecitabine's carbamate side chain to form 5′-deoxy-5-fluorocytidine (5′-DFCR). This study examines the steady-state kinetics of recombinant human carboxylesterase isozymes carboxylesterase (CES) 1A1, CES2, and CES3 for hydrolysis of capecitabine with a liquid chromatography/mass spectroscopy assay. Additionally, a spectrophotometric screening assay was utilized to identify drugs that may inhibit carboxylesterase activation of capecitabine. CES1A1 and CES2 hydrolyze capecitabine to a similar extent, with catalytic efficiencies of 14.7 and 12.9 min-1 mM-1, respectively. Little catalytic activity is detected for CES3 with capecitabine. Northern blot analysis indicates that relative expression in intestinal tissue is CES2 > CES1A1 > CES3. Hence, intestinal activation of capecitabine may contribute to its efficacy in colon cancer and toxic diarrhea associated with the agent. Loperamide is a strong inhibitor of CES2, with a Ki of 1.5 μM, but it only weakly inhibits CES1A1 (IC50 = 0.44 mM). Inhibition of CES2 in the gastrointestinal tract by loperamide may reduce local formation of 5′-DFCR. Both CES1A1 and CES2 are responsible for the activation of capecitabine, whereas CES3 plays little role in 5′-DFCR formation.

Original languageEnglish
Pages (from-to)1011-1016
Number of pages6
JournalJournal of Pharmacology and Experimental Therapeutics
Volume313
Issue number3
DOIs
StatePublished - Jun 2005

Fingerprint

Carboxylic Ester Hydrolases
Loperamide
Hydrolysis
Carboxylesterase
Fluorouracil
Thymidine Phosphorylase
Cytidine Deaminase
Capecitabine
5'-deoxy-5-fluorocytidine
Carbamates
Poisons
Prodrugs
Liquid Chromatography
Northern Blotting
Colonic Neoplasms
Isoenzymes
Inhibitory Concentration 50
Gastrointestinal Tract
Colorectal Neoplasms
Diarrhea

ASJC Scopus subject areas

  • Pharmacology

Cite this

Hydrolysis of capecitabine to 5′-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. / Quinney, Sara; Sanghani, S. P.; Davis, W. I.; Hurley, Thomas; Sun, Z.; Murry, D. J.; Bosron, William F.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 313, No. 3, 06.2005, p. 1011-1016.

Research output: Contribution to journalArticle

@article{eb6b0c82d8244895b8ca0cea4f3b9694,
title = "Hydrolysis of capecitabine to 5′-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide",
abstract = "Capecitabine is an oral prodrug of 5-fluorouracil that is indicated for the treatment of breast and colorectal cancers. A three-step in vivo-targeted activation process requiring carboxylesterases, cytidine deaminase, and thymidine phosphorylase converts capecitabine to 5-fluorouracil. Carboxylesterases hydrolyze capecitabine's carbamate side chain to form 5′-deoxy-5-fluorocytidine (5′-DFCR). This study examines the steady-state kinetics of recombinant human carboxylesterase isozymes carboxylesterase (CES) 1A1, CES2, and CES3 for hydrolysis of capecitabine with a liquid chromatography/mass spectroscopy assay. Additionally, a spectrophotometric screening assay was utilized to identify drugs that may inhibit carboxylesterase activation of capecitabine. CES1A1 and CES2 hydrolyze capecitabine to a similar extent, with catalytic efficiencies of 14.7 and 12.9 min-1 mM-1, respectively. Little catalytic activity is detected for CES3 with capecitabine. Northern blot analysis indicates that relative expression in intestinal tissue is CES2 > CES1A1 > CES3. Hence, intestinal activation of capecitabine may contribute to its efficacy in colon cancer and toxic diarrhea associated with the agent. Loperamide is a strong inhibitor of CES2, with a Ki of 1.5 μM, but it only weakly inhibits CES1A1 (IC50 = 0.44 mM). Inhibition of CES2 in the gastrointestinal tract by loperamide may reduce local formation of 5′-DFCR. Both CES1A1 and CES2 are responsible for the activation of capecitabine, whereas CES3 plays little role in 5′-DFCR formation.",
author = "Sara Quinney and Sanghani, {S. P.} and Davis, {W. I.} and Thomas Hurley and Z. Sun and Murry, {D. J.} and Bosron, {William F.}",
year = "2005",
month = "6",
doi = "10.1124/jpet.104.081265",
language = "English",
volume = "313",
pages = "1011--1016",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Hydrolysis of capecitabine to 5′-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide

AU - Quinney, Sara

AU - Sanghani, S. P.

AU - Davis, W. I.

AU - Hurley, Thomas

AU - Sun, Z.

AU - Murry, D. J.

AU - Bosron, William F.

PY - 2005/6

Y1 - 2005/6

N2 - Capecitabine is an oral prodrug of 5-fluorouracil that is indicated for the treatment of breast and colorectal cancers. A three-step in vivo-targeted activation process requiring carboxylesterases, cytidine deaminase, and thymidine phosphorylase converts capecitabine to 5-fluorouracil. Carboxylesterases hydrolyze capecitabine's carbamate side chain to form 5′-deoxy-5-fluorocytidine (5′-DFCR). This study examines the steady-state kinetics of recombinant human carboxylesterase isozymes carboxylesterase (CES) 1A1, CES2, and CES3 for hydrolysis of capecitabine with a liquid chromatography/mass spectroscopy assay. Additionally, a spectrophotometric screening assay was utilized to identify drugs that may inhibit carboxylesterase activation of capecitabine. CES1A1 and CES2 hydrolyze capecitabine to a similar extent, with catalytic efficiencies of 14.7 and 12.9 min-1 mM-1, respectively. Little catalytic activity is detected for CES3 with capecitabine. Northern blot analysis indicates that relative expression in intestinal tissue is CES2 > CES1A1 > CES3. Hence, intestinal activation of capecitabine may contribute to its efficacy in colon cancer and toxic diarrhea associated with the agent. Loperamide is a strong inhibitor of CES2, with a Ki of 1.5 μM, but it only weakly inhibits CES1A1 (IC50 = 0.44 mM). Inhibition of CES2 in the gastrointestinal tract by loperamide may reduce local formation of 5′-DFCR. Both CES1A1 and CES2 are responsible for the activation of capecitabine, whereas CES3 plays little role in 5′-DFCR formation.

AB - Capecitabine is an oral prodrug of 5-fluorouracil that is indicated for the treatment of breast and colorectal cancers. A three-step in vivo-targeted activation process requiring carboxylesterases, cytidine deaminase, and thymidine phosphorylase converts capecitabine to 5-fluorouracil. Carboxylesterases hydrolyze capecitabine's carbamate side chain to form 5′-deoxy-5-fluorocytidine (5′-DFCR). This study examines the steady-state kinetics of recombinant human carboxylesterase isozymes carboxylesterase (CES) 1A1, CES2, and CES3 for hydrolysis of capecitabine with a liquid chromatography/mass spectroscopy assay. Additionally, a spectrophotometric screening assay was utilized to identify drugs that may inhibit carboxylesterase activation of capecitabine. CES1A1 and CES2 hydrolyze capecitabine to a similar extent, with catalytic efficiencies of 14.7 and 12.9 min-1 mM-1, respectively. Little catalytic activity is detected for CES3 with capecitabine. Northern blot analysis indicates that relative expression in intestinal tissue is CES2 > CES1A1 > CES3. Hence, intestinal activation of capecitabine may contribute to its efficacy in colon cancer and toxic diarrhea associated with the agent. Loperamide is a strong inhibitor of CES2, with a Ki of 1.5 μM, but it only weakly inhibits CES1A1 (IC50 = 0.44 mM). Inhibition of CES2 in the gastrointestinal tract by loperamide may reduce local formation of 5′-DFCR. Both CES1A1 and CES2 are responsible for the activation of capecitabine, whereas CES3 plays little role in 5′-DFCR formation.

UR - http://www.scopus.com/inward/record.url?scp=19444380386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19444380386&partnerID=8YFLogxK

U2 - 10.1124/jpet.104.081265

DO - 10.1124/jpet.104.081265

M3 - Article

C2 - 15687373

AN - SCOPUS:19444380386

VL - 313

SP - 1011

EP - 1016

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -